 |
Previous Article | Next Article 
The Journal of Neuroscience, March 15, 1999, 19(6):2301-2312
A Glial Cell Line-Derived Neurotrophic Factor-Secreting Clone of
the Schwann Cell Line SCTM41 Enhances Survival and Fiber
Outgrowth from Embryonic Nigral Neurons Grafted to the Striatum and to
the Lesioned Substantia Nigra
Martin J.
Wilby1,
Simon
R.
Sinclair1,
Elizabeth M.
Muir2,
Rike
Zietlow1, 2,
Kathryn H.
Adcock1, 2,
Philippe
Horellou4,
John H.
Rogers2,
Stephen B.
Dunnett1, 3, and
James W.
Fawcett1, 2
1 Medical Research Council, Cambridge Centre for
Brain Repair, The E. D. Adrian Building, University of Cambridge,
Forvie Site, Robinson Way, Hills Road, Cambridge CB2 2PY, United
Kingdom, 2 Physiological Laboratory, University of
Cambridge, Downing Site, Cambridge CB1 3EG, United Kingdom,
3 Department of Experimental Psychology, University of
Cambridge, Downing Site, Cambridge CB2 3EG, United Kingdom, and
4 C 9923 Centre National de la Recherche Scientifique,
Laboratoire de Genetique Moleculaire de la Neurotransmission et des
Processus Degeneratifs, Hopital de la Pitie Salpetriere, Batiment
CERVI, 75013 Paris, France.
We have developed a novel Schwann cell line, SCTM41, derived
from postnatal sciatic nerve cultures and have stably transfected a
clone with a rat glial cell line-derived neurotrophic factor (GDNF) construct. Coculture with this GDNF-secreting
clone enhances in vitro survival and fiber growth of
embryonic dopaminergic neurons. In the rat unilateral 6-OHDA lesion
model of Parkinson's disease, we have therefore made cografts of these
cells with embryonic day 14 ventral mesencephalic grafts and
assayed for effects on dopaminergic cell survival and process
outgrowth. We show that cografts of GDNF-secreting Schwann cell lines
improve the survival of intrastriatal embryonic dopaminergic neuronal
grafts and improve neurite outgrowth into the host neuropil but have no
additional effect on amphetamine-induced rotation. We next looked to
see whether bridge grafts of GDNF-secreting SCTM41 cells would promote the growth of axons to their striatal targets from dopaminergic neurons
implanted orthotopically into the 6-OHDA-lesioned substantia nigra. We
show that such bridge grafts increase the survival of implanted
embryonic dopaminergic neurons and promote the growth of axons through
the grafts to the striatum.
Key words:
bridge graft; GDNF; Parkinson's disease; 6-OHDA; Schwann
cells; SCTM41; substantia nigra; neuronal graft
Copyright © 1999 Society for Neuroscience 0270-6474/99/1962301-12$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
S. Johansson, I-H. Lee, L. Olson, and C. Spenger
Olfactory ensheathing glial co-grafts improve functional recovery in rats with 6-OHDA lesions
Brain,
December 1, 2005;
128(12):
2961 - 2976.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. -L. Kuan and R. A. Barker
New Therapeutic Approaches to Parkinson's Disease Including Neural Transplants
Neurorehabil Neural Repair,
September 1, 2005;
19(3):
155 - 181.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Lawrence, D. J. Keegan, E. M. Muir, P. J. Coffey, J. H. Rogers, M. J. Wilby, J. W. Fawcett, and R. D. Lund
Transplantation of Schwann Cell Line Clones Secreting GDNF or BDNF into the Retinas of Dystrophic Royal College of Surgeons Rats
Invest. Ophthalmol. Vis. Sci.,
January 1, 2004;
45(1):
267 - 274.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Nikkhah, G. Falkenstein, and C. Rosenthal
Restorative Plasticity of Dopamine Neuronal Transplants Depends on the Degree of Hemispheric Dominance
J. Neurosci.,
August 15, 2001;
21(16):
6252 - 6263.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Kirik, C. Winkler, and A. Bjorklund
Growth and Functional Efficacy of Intrastriatal Nigral Transplants Depend on the Extent of Nigrostriatal Degeneration
J. Neurosci.,
April 15, 2001;
21(8):
2889 - 2896.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Brundin, O. Pogarell, P. Hagell, P. Piccini, H. Widner, A. Schrag, A. Kupsch, L. Crabb, P. Odin, B. Gustavii, et al.
Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease
Brain,
July 1, 2000;
123(7):
1380 - 1390.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|